Magenta Therapeutics Presents Final Phase 1 Results of MGTA-145 Stem Cell Mobilization Clinical Trial and Preclinical Data from Targeted Conditioning Program at the European Society for Blood and Marrow Transplantation 2021 Annual Meeting
March 15, 2021 at 08:00 am EDT
Share
Magenta Therapeutics announced availability of data presentations across its stem cell mobilization and targeted conditioning programs at the European Society for Blood and Marrow Transplantation (EBMT) 2021 annual meeting, held virtually March 14-17, 2021. Magenta is developing MGTA-145 plus plerixafor to harness these agents’ complementary mechanisms to mobilize hematopoietic stem cells (HSCs) for collection and transplantation, including for use with gene therapies. The ability to provide rapid, reliable, predictable and safe mobilization and collection of HSCs in stem cell transplantation could position MGTA-145 plus plerixafor to be the preferred mobilization regimen across multiple diseases due to improved patient experience and collection outcomes. Data from this Phase 1 clinical trial with healthy volunteers further underscore the potential utility of MGTA-145 plus plerixafor as an effective, single-day mobilization and collection regimen for autologous and allogeneic HSC transplant. MGTA-145 plus plerixafor rapidly mobilized large numbers of HSCs and showed durable engraftment, successful gene-modification and immunosuppressive properties by reducing Graft-versus-Host disease (GvHD) in preclinical models. This abstract is an encore presentation by the Company. Magenta is developing a platform of novel antibody-drug conjugates (ADCs) for conditioning, a step in the transplant process that currently relies on the use of systemic chemotherapy agents and radiation. Magenta’s targeted conditioning programs are designed to selectively eliminate stem cells and/or immune cells from a patient prior to stem cell transplant or gene therapy. The conditioning ADCs have the potential to reduce or eliminate the need for high dose or high intensity chemotherapy-based conditioning regimens. MGTA-117, Magenta’s most advanced conditioning program, is a CD117-targeted antibody conjugated to amanitin and intended for use in patients undergoing transplant or gene therapy. MGTA-117 is designed to deplete hematopoietic stem cells and clear space in the bone marrow prior to transplant to enable long-term engraftment and improved disease outcomes in patients. MGTA-117 has shown high selectivity, potent efficacy and tolerability in multiple preclinical studies. The Company expects to file an Investigational New Drug (IND) application for MGTA-117 in mid-2021, and, upon acceptance of the IND by the U.S. FDA, Magenta plans to initiate a Phase 1/2 clinical trial to evaluate MGTA-117 in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), with initial safety and pharmacokinetic data available for internal assessment by Fourth Quarter 2021. These initial data are expected to be directional for the Company’s dose escalation plans.
Magenta Therapeutics, Inc. is a biotechnology company focused on improving stem cell transplantation. The Company is developing medicines designed to bring the curative power of stem cell transplants to more patients with blood cancers, genetic diseases, and autoimmune diseases. Its drug development pipeline includes multiple product candidates designed to improve stem cell transplants. Its lead clinical program is designed to mobilize and collect sufficient functional stem cells for use in stem cell transplantation, a process known as mobilization. It is also developing product candidates that are designed to deplete targeted cells in the bone marrow to make space for the bone marrow to receive newly transplanted stem cells, a process known as conditioning. Its pipeline of stem cell transplant product candidates consists of MGTA-117, MGTA-145, CD45-ADC, and its research platform. The MGTA-117 program is designed to selectively deplete stem cells from patients prior to transplant.
Magenta Therapeutics Presents Final Phase 1 Results of MGTA-145 Stem Cell Mobilization Clinical Trial and Preclinical Data from Targeted Conditioning Program at the European Society for Blood and Marrow Transplantation 2021 Annual Meeting